Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:antibiotic
cephalosporin second-generation cephalosporin |
| gptkbp:ATCCode |
J01DC02
|
| gptkbp:bioavailability |
37-52% (oral)
|
| gptkbp:brand |
Ceftin
Kefurox Zinacef |
| gptkbp:CASNumber |
55268-75-2
|
| gptkbp:chemicalFormula |
C16H16N4O8S
|
| gptkbp:contraindication |
hypersensitivity to cephalosporins
|
| gptkbp:discoveredBy |
Glaxo (now GSK)
|
| gptkbp:drugClass |
gptkb:antibiotic
|
| gptkbp:eliminationHalfLife |
1-1.5 hours
|
| gptkbp:excretion |
renal
|
| https://www.w3.org/2000/01/rdf-schema#label |
Cefuroxime
|
| gptkbp:introducedIn |
1978
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits bacterial cell wall synthesis
|
| gptkbp:metabolism |
not significantly metabolized
|
| gptkbp:molecularWeight |
424.39 g/mol
|
| gptkbp:pregnancyCategory |
B (US)
B1 (Australia) |
| gptkbp:prescribes |
adults
children |
| gptkbp:proteinBinding |
33-50%
|
| gptkbp:resistantTo |
some bacteria produce beta-lactamases that inactivate cefuroxime
|
| gptkbp:routeOfAdministration |
oral
intramuscular intravenous |
| gptkbp:sideEffect |
nausea
vomiting diarrhea rash elevated liver enzymes allergic reactions eosinophilia |
| gptkbp:spectrumOfActivity |
broad-spectrum
|
| gptkbp:usedFor |
gptkb:sinusitis
skin infections tonsillitis urinary tract infections gonorrhea bacterial infections otitis media respiratory tract infections pharyngitis |
| gptkbp:WHOModelListOfEssentialMedicines |
true
|
| gptkbp:bfsParent |
gptkb:Streptomyces_species
|
| gptkbp:bfsLayer |
6
|